Akero reaffirms commitment within Novo family
The biotech company unveils a refreshed brand identity while emphasizing its continued dedication to advancing lasting health alongside its parent organization.
Latest Akero Therapeutics News & Updates
See the latest news and media coverage for Akero. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing metabolic disease therapies
akerotx.com- Headquarters
- South San Francisco, United States
- Founded year
- 2017
- Company type
- Public company
- Number of employees
- 10–80
- Industry
- Pharmaceuticals
Last updated
Latest news about Akero Therapeutics (Akero)
In short: Akero was acquired by Novo Nordisk for up to $5.2 billion following successful Phase 2b results for its MASH treatment, efruxifermin.
Company announcements
Akero Therapeutics reflects on 2025 achievements
They showed cirrhosis reversal in Phase 2b trial, completed Phase 3 enrollment, and finalized Novo Nordisk acquisition. They anticipate 2026 progress.
Akero Therapeutics completes acquisition by Novo Nordisk
This milestone advances efruxifermin for MASH treatment, complementing Novo Nordisk's metabolic disease portfolio.
Akero Therapeutics shares new efruxifermin data at AASLD
They present posters and oral sessions on antifibrotic activity from SYMMETRY and HARMONY trials.
Media coverage
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Under the terms of the deal, Novo Nordisk will initially pay $54 a share in cash, or $4.7 billion, upon closing. Akero shareholders will also...
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics | PharmExec
Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic dysfunction-associated steatohepatitis.
What Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeutics
Avoro Capital Advisors sold its entire stake in Akero Therapeutics for $187.81 million. This strategic exit followed Novo Nordisk's $5.2 billion acquisition of Akero. The...
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero ...
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale...
Never miss news about Akero
Track Akero and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Akero competitors & trending companies
Browse news for competitors to Akero and other trending companies.
MediciNova
Structure
BioAge Labs
Viking Therapeutics
Can-Fite
Oculis
Ticketplus
HELP Therapeutics
CMC
ManpowerGroup
Arcosa
Alliance Entertainment
QXO
Reliant Stones
Amber
The Pool Tile Co
Cinajus
Armstone
Eco Outdoor
Sareen Stone
Stone Planet
Salience Labs
Trio Petroleum
Arianespace
American Eagle
AEO
OLB
Compass
MAQS
Roschier
Möller & Partners
Normain
Incentive Industrier
Pinecone